Introduction
============

Neuroinflammation is an important feature in the pathogenesis and progression of neurodegenerative diseases such as Alzheimer´s disease (AD), Parkinson´s disease (PD), frontotemporal dementia and amyotrophic lateral sclerosis \[[@R1]-[@R8]\]. Brains from patients with neurodegenerative diseases are characterized by marked astrocytosis, activation of microglia and elevated levels of pro-inflammatory cytokines \[[@R8],[@R10]-[@R12]\].

Epidemiological studies indicate that AD and PD risk positively correlates with pro-inflammatory conditions such as diabetes mellitus, metabolic syndrome, hyper-cholesterolemia and atherosclerosis suggesting that chronic inflammation may influence the development of neurodegenerative diseases (for detailed reviews see Refs. \[[@R13]-[@R17]\]). In addition, it has been recently reported that peripheral infections accompanied by inflammation represent major risk factors for the development of sporadic AD and PD \[[@R18]-[@R20]\].

Based on current knowledge in the field, suggesting that targeting peripheral inflammation could be a promising additional treatment/prevention approach for neuro-degenerative diseases, drugs and natural products with anti-inflammatory properties have been evaluated in animal models of neuroinflammation and neurodegeneration (for a review see Ref. \[[@R21]\]). In this review, we will first provide an extensive analysis of one of the most important and widely-used animal models of peripherally induced neuro-inflammation and neurodegeneration - lipopolysaccharide (LPS)-treated mice. We will address data reproducibility as well as different experimental approaches in analyzed literature. LPS, an endotoxin from the outer membrane of bacteria, is known as a potent trigger of inflammation. It has been demonstrated that peripheral administration of LPS in mice induced astrocyte and microglia activation, as well as cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokine expression in the brain \[[@R22]-[@R25]\]. In addition, intracellular accumulation of amyloid precursor protein, amyloid β peptide and hyperphosphorylated tau as well as exacerbation of memory deficits were observed in LPS-treated APP transgenic mice \[[@R26],[@R27]\].

We will also provide an overview of studies on anti-inflammatory properties of various natural products, nutraceuticals, tested in LPS-treated mice.

NEUROINFLAMMATION AND NEURODEGENERATION INDUCED BY PERIPHERAL ADMINISTRATION OF LPS
===================================================================================

Activated Microglia and Pro-inflammatory Cytokines
--------------------------------------------------

It is widely accepted that microglia, the principal effector cells of the immune system in the brain, in addition to being key actors for host defense in brain injury and disease (for comprehensive reviews see Refs. \[[@R28]-[@R31]\]), play an important role in the healthy brain physiology and synaptic remodeling associated with learning and memory probably by releasing neurotrophic factors like BDNF \[[@R32]\]. During an inflammatory response, activation of microglia leads to retraction of their processes and swelling of the cell bodies with subsequent loss of brain monitoring, and this may induce neuronal damage, disruption of relevant circuits and, in the case of uncontrolled or chronic neuroinflammation, functional decline (for a review, see Ref. \[[@R32]\]).

After single or multiple peripheral treatment of mice with LPS, the increase in the numbers of F4/80-, CD11-, CD45- or Iba-1-positive cells as well as morphological changes characteristic for activated microglia were observed in numerous studies \[[@R22],[@R26],[@R27],[@R33]-[@R36]\]. However, there are also reports where authors did not observe microglia activation after single i.p. injection of LPS, although after multiple administration activated microglia were detected \[[@R37],[@R38]\].

It has been well documented that peripherally-injected LPS induced a variety of central effects mediated, in part, by pro-inflammatory cytokines released mainly from microglia. Although it is generally accepted that cytokines released in periphery do not diffuse across the blood-brain barrier (BBB), but they may transfer the signal to the brain \[[@R39]-[@R41]\], numerous studies in animals demonstrated that LPS is capable of stimulating from periphery the synthesis of pro-inflammatory cytokines in the brain \[[@R42]-[@R45]\]. However, despite the abundant literature available, the data on the presence of the main pro-inflammatory cytokines in the brain after LPS challenge differ according to different authors. The discrepancies in the results reported could be due to the numerous experimental details that are differing in all available reports: LPS or mouse strain used, site of injection, quantity of LPS applied, time after the challenge mice were sacrificed *etc*.

First studies reported robust and transient expression of interleukin-1β (IL-1β), IL-6 and TNF-α mRNA in various brain regions assessed by the reverse transcription polymerase chain reaction (RT-PCR) \[[@R42],[@R44],[@R46]-[@R49]\]. Different strains of mice (both males and females) were used in these studies: CH3/He, B6C3F1, C57BL/6J and CD-1. Intravenous or intraperitoneal injection of LPS at doses ranging from 0.02 mg/kg to 3 mg/kg was another variable in these studies. Moreover, mice were sacrificed at different time after the challenge, and this may explain, in part, different outcome seen because at certain concentrations LPS induces transient disease.

Subsequently, more studies were performed in wild type mice as well as in murine models of different neuro-degenerative diseases (AD, PD, ALS *etc*) using animals of different ages and, again, elevated and prolonged expression of IL-1β, IL-6 and TNF-α mRNA as well as proteins was documented in various brain regions after single or multiple peripheral administration of LPS. In the Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}** we are summarizing most frequently used protocols and their outcome published recently. Cited papers, in turn, contain extensive review of previous work.

As can be seen, even in the case of the same mouse and LPS strain and almost similar experimental procedure, some authors observed elevated pro-inflammatory cytokines in the brain while others did not. Some authors measured both mRNA and protein levels while others evaluated (or reported) only mRNA or protein data. In some cases, it is not clear if the absence of a given cytokine is because authors measured it and obtained negative results or they did not perform the evaluation. Another important issue to be considered is the psychological stress that may lead to a pro-inflammatory status of the brain and to exaggerated microglia activation, and differences in animal management and care in the different laboratories may explain, in part, heterogeneity of results \[[@R57],[@R58]\]. However, certain reproducibility among different laboratories exists, and one may conclude that 1) peripheral administration of LPS leads to exacerbated neuroinflammation in old *vs* adult mice; 2) high doses as well as multiple administration of LPS increase the expression of pro-inflammatory cytokines in the brain. In biomedical research, the convergence of different methods for evaluating the same phenomena is another important issue, and, as can be seen below in Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**, the elevated expression of pro-inflammatory cytokines was documented using different experimental approaches, like RT-PCR, ELISA, WB, FACS and immunocytochemistry.

An important point to be considered when using this model should be the mouse strain. Thus, C57BL/6J and FVB/NL mice were shown to be highly susceptible to systemic LPS challenge while A/J, C3H/HeJ and 129S1/SvImJ were reported to be resistant \[[@R59]-[@R61]\]. However, in another study from Yang's group, C57BL/6J mice were found to be resistant \[[@R62]\]. The great majority of APP-Tg mice as well as mouse models for Parkinson disease have mixed C57BL/6Jx129S1/Sv, C57BL/6JxSJL or C57BL/6JxC3H/HeJ background, and it is difficult to guess their susceptibility to systemic LPS \[[@R63]-[@R72]\].

Some unique observations were also reported. Thus, while the majority of studies in this model pointed to destructive role of activated microglia and molecules released and demonstrated M-1 (pro-inflammatory) cytokine profile, Chen and collaborators reported that one or multiple i.p. injections of 1mg/kg LPS prime microglia toward M2 (anti-inflammatory) phenotype and may lead to neuroprotection, and suggested LPS preconditioning for therapeutic applications to benefit patients who suffer from neurodegenerative diseases or brain trauma \[[@R38]\]. One likely reason for these contradictory results may be slightly different experimental conditions used. Also, it is also important to mention that in the latter study authors did not include (or did not report) in microarray analysis of M-1-related genes two important pro-inflammatory cytokines, IL-6 and IL-1β, known to be expressed in the brain of i.p. LPS-treated mice. Instead, they observed no changes in iNOS and TNF-α genes, in agreement with some previous research.

In conclusion, whether i.p. LPS injection in mice will have neurotoxic or neuroprotective effect, will depend on experimental conditions, and there are examples included in Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**.

Astrogliosis
------------

Astrocytes, the most abundant cell type in the CNS, have many essential functions in the healthy brain and respond to different forms of damage through a process called astrogliosis (for extensive recent reviews see Ref. \[[@R73]-[@R75]\]). Although the astrogliosis was shown to be a beneficial process to protect neurons and repair the tissue after CNS insult, under specific conditions reactive astrocytes can exacerbate neuroinflammation and tissue damage (for detailed reviews see Ref. \[[@R75]-[@R77]\]).

In LPS-treated mice an increase in the number of glial fibrillary acidic protein (GFAP)-positive cells and up-regulation of GFAP expression at different time points after challenge as well as astrocyte hypertrophy were reported by some laboratories \[[@R25],[@R26],[@R34],[@R35],[@R58]\] while others did not observe such an increase \[[@R78]\].

iNOS and COX-2
--------------

Two pro-inflammatory effector enzymes, iNOS and COX-2, are induced and up-regulated upon inflammation and known to contribute to neurodegeneration. There is no detectable iNOSgene expression in the brain at baseline, while COX-2 was found to be expressed under normal conditions too and to participate in fundamental brain functions such as synaptic plasticity and memory consolidation (for a review see Refs. \[[@R79]-[@R81]\]). Enhanced expression of iNOS during an inflammatory response can increase the local production of NO which has been suggested to be involved in neurodegenerative processes, including the inhibition of mitochondrial respiration, axonal and synaptic damage, and the induction of neuronal apoptosis \[[@R82]-[@R85]\]. Genetic ablation and pharmacological inhibition of iNOS has been shown to protect mice from spatial memory dysfunction and depressive-like behavior \[[@R86],[@R87]\].

Numerous studies demonstrated increased levels of iNOS and COX-2 mRNA and protein in the brains of i.p. LPS-treated mice using RT-PCR, WB or immunohistochemistry \[[@R24],[@R49],[@R88]-[@R90]\]. While levels of mRNA picked between 3 and 6 h and then decreased to basal levels at 12-24 h after LPS treatment, elevated iNOS and COX-2 protein were detected by WB and immunohistochemistry at 6, 24 h and 3 days \[[@R35],[@R88],[@R91],[@R92]\]. Interestingly, induction of COX-2 occurred mainly in brain endothelia \[[@R89],[@R91],[@R93]\] and was not significantly region-specific \[[@R89]\]. However, Okuyama and collaborators detected COX-2 in activated astrocytes but not microglia after i.p. LPS injection \[[@R35]\]. COX-2 immuno-reactivity was observed mainly around the nuclear envelope as well as in dendritic and axonal domains \[[@R88],[@R93]\].

Up-regulation of iNOS was also evaluated by measuring the activation of the NO pathway after peripheral administration of LPS \[[@R94]\].

Synaptic Failure and Cognitive Dysfunction
------------------------------------------

It has been demonstrated that neuroinflammation impaired synaptic plasticity in the hippocampus, disrupted hippocampal-dependent learning and memory and increased neuronal death \[[@R37],[@R95]-[@R97]\]. These phenomena were also addressed in mice after single or multiple peripheral LPS administration. Authors detected increased neuronal apoptosis, progressive loss of dopaminergic neurons, reduced expression of brain-derived neurotrophic factor (BDNF), reduced serotonin release by serotonergic neurons, decreased levels of autophagy markers, reduced social behavior and locomotor activity as well as impaired performance in various learning and memory tasks, including two-way active avoidance conditioning test and the Morris water maze \[[@R22],[@R35],[@R37],[@R50],[@R51],[@R54]-[@R56],[@R96],[@R98]-[@R101]\]. Young and old C57BL/6J and BALB/c mice were used, and, as expected, greater cognitive dysfunction was observed in old animals reflecting higher neuroinflammation in elderly \[[@R51],[@R99]\]. However, it is noteworthy to mention findings reported by Sparkman and collaborators that old mice given repeated LPS injections had significantly longer latencies compared with controls, but authors contributed these results to reduced swim speed as well as anxiety-like symptoms and not necessarily to learning and memory dysfunction \[[@R99]\]. On the other hand, in a recent study by Ormerod and collaborators, swim speeds in C57BL/6J female mice (7-8 weeks-old) were unaffected one week after single intraperitoneal challenge with 5mg/kg LPS \[[@R102]\]. In addition, no statistically significant effect of LPS on learning and memory on hidden platform trials was observed one week later in these animals. Four weeks after challenge LPS-treated mice manifested latent spatial memory impairment but their ability to either learn a novel hidden platform location or locate a visible platform was similar to control group \[[@R102]\]. Finally, authors demonstrated that peripheral LPS compromises hippocampal neurogenesis \[[@R102]\].

Exacerbation of AD-like Pathology in APP-transgenic Mice
--------------------------------------------------------

Few studies were performed in APP-transgenic mice to evaluate the effect of peripherally administered LPS \[[@R26],[@R27],[@R33],[@R103]\]. In the first study, Sheng and collaborators treated with LPS adult APPswe Tg mice intraperitoneally once a week for 12 weeks and observed microglia activation as determined by the increase in F4/80(+) cells \[[@R26]\]. In addition, LPS treatment increases brain levels of APP, APP C-terminal fragments and Aβ1-40/42 as determined by immunohistochemical analysis and western blotting \[[@R26]\]. Subsequently, the effect of a systemic challenge with LPS on brain was assessed in three studies in 3xTg-AD mice that develop both Aβ and tau pathology \[[@R27],[@R33],[@R103]\]. All three studies used the same LPS strain, but other experimental conditions were not similar. In summary, i.p. LPS treatment of young adult (4-month-old) 3xTg-AD mice twice per week for 6 weeks induced microglial activation, IL-1β expression and tau phosphorylation, but unlike in the previous report by Sheng and collaborators \[[@R26]\], did not affect APP processing and Aβ deposition \[[@R27]\]. No significant effect of LPS on the onset and progression of Aβ pathology was observed in 12-month-old 3xTg-AD mice treated by using the same protocol \[[@R33]\]. However, in the latter study authors also observed exacerbation of tau pathology as well as learning and memory impairments in LPS-treated mice \[[@R33]\]. Finally, Valero and collaborators demonstrated that a single i.p. injection of LPS in 3xTG-AD mice has a long-term impact on adult neurogenesis and lead to the development of memory deficits \[[@R103]\].

All these studies suggested that systemic LPS-induced inflammation may trigger neuroinflammation with subsequent Aβ and/or tau pathology, neurodegeneration and cognitive decline.

NUTRACEUTICALS: PRECLINICAL STUDIES IN LPS-INDUCED NEUROINFLAMMATION MODEL
==========================================================================

As an important and widely-used animal model of peripherally induced neuroinflammation and neuro-degeneration, LPS-treated mice were also widely used to screen synthetic drugs and natural products. This review will focus on natural products with therapeutic properties known as nutraceuticals and used to reduce LPS-induced neuro-inflammation in mouse brain. Comprehensive review on nutraceuticals with anti-inflammatory and neuroprotective properties in other models as well as possible multiple mechanisms of their action may be found elsewhere \[[@R104]-[@R108]\].

Resveratrol
-----------

Resveratrol is a polyphenol found mainly in grapes and red vine and shown to confer protection *in vitro* and *in vivo*against oxidative stress, inflammatory and cardiovascular diseases, cancer as well as neuropathology associated with neurodegenerative diseases, brain trauma and cerebral ischemia (see excellent recent reviews Refs. \[[@R109]-[@R111]\]).

It has been shown that dietary supplementation of resveratrol during four weeks reduced IL-1β mRNA in the hippocampus of aged (22-24 months) male BALB/c mice treated intraperitoneally with LPS \[[@R112]\]. Interestingly, in this study resveratrol did not affect LPS-induced sickness behavior in young adult mice (3-6 months) at any time post-injection, however, ameliorated LPS-induced locomotor deficits in aged (22-24 months) mice beginning at 8 h \[[@R112]\]. In addition, resveratrol completely blocked LPS-induced inhibition of working memory in aged mice \[[@R112]\]. In another study, adult male Swiss Albino mice were daily i.p. injected with resveratrol during 7 days and then challenged by a single i.p. administration of LPS (4mg/kg) \[[@R113]\]. Authors showed that resveratrol increases the survival rate, abolished NO elevation to near control levels and counteracted all LPS-induced iron disturbances in the brain \[[@R113]\]. Protective effects of resveratrol on memory decline were also observed in mice first treated i.p. with LPS to induce neuroinflammation and then injected with resveratrol for 7 days, suggesting possible therapeutic application \[[@R114]\].

Curcumin
--------

Curcumin, the main ingredient of the Indian spice turmeric, was shown to display anti-inflammatory, anti-oxidant, anti-cancer and anti-bacterial properties by multiple mechanisms (see comprehensive recent reviews Refs. \[[@R115]-[@R119]\]). In mouse model of neuroinflammation induced by i.p. LPS injection, curcumin was able to reduce iNOS and IL-1β levels in the brain \[[@R120]\]. Wang and collaborators demonstrated that pretreatment with curcumin (50 mg/kg, i.p.) for 7 consecutive days reverses i.p. LPS-induced alterations in the forced swimming, tail suspension and sucrose preference tests and attenuates microglial activation and overproduction of pro-inflammatory cytokines (IL-1β and TNF-α) as well as levels of iNOS and COX-2 mRNA in the hippocampus and prefrontal cortex of adult male Kun-Ming mice \[[@R121]\]. Because of its insolubility in water, poor bioavailability and difficulty to cross blood-brain barrier, curcumin has to be used with new delivery systems. One of these strategies was tested in LPS-treated mice \[[@R122]\]. Authors demonstrated that intranasally administered exosome encapsulated curcumin is rapidly transported to the brain and inhibits i.p. LPS-induced increase in brain IL-1β as detected by FACS and RT-PCR analysis in C57BL/6J mice \[[@R122]\].

Ginsenosides and Glycyrrhizin
-----------------------------

Ginsenosides are ginseng saponins shown to modulate inflammatory processes, as well as to inhibit neuron death, mitochondrial dysfunction and tumor growth \[[@R123]-[@R126]\]. In LPS-induced neuroinflammation model ginsenoside Rg~3~ has been demonstrated to attenuate pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) mRNA expression in the brain \[[@R24]\]. In addition, inhibition of microglia activation (evaluated by Western blot and immunohistochemistry using anti-Iba 1 antibody) and iNOS and COX-2 expression (evaluated by immunohistochemistry) in the brain of i.p. LPS-treated C57BL/6J adult male mice was observed after oral administration of Rg~3~\[[@R24]\]. In another study, Lee and collaborators demonstrated that ginsenoside Rb1 reduced microglia activation and pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) and COX-2 mRNA expression in the brain following single i.p. administration of 3 mg/kg of LPS \[[@R127]\]. In this study, COX-2 reduction was also observed by IHQ \[[@R127]\].

Glycyrrhizin (GRZ), a triterpenoid saponin compound composed of one molecule of glycyrrhetinic acid and two molecules of glucuronic acid, was shown to have anti-inflammatory and neuroprotective effects *in vitro* and *in vivo*\[[@R128]-[@R130]\]. In peripherally LPS-treated C57BL/6J mice, orally administered GRZ significantly reduced brain expression of TNF-a, IL-1β, iNOS and COX-2 as determined by RT-PCR, immunohistochemical analysis and western blotting \[[@R92]\]. Also, authors demonstrated that GRZ ameliorates the memory deficits as observed in Morris water maze test \[[@R92]\].

Oenothein B
-----------

Oenothein B, a dimeric macrocyclic ellagitannin, was shown to have anti-inflammatory, anti-oxidant and anti-tumor activity both *in vitro and in vivo*\[[@R131]-[@R133]\]. Okuyama and collaborators showed that oenothein B suppresses microglial activation and COX-2 production in the hippocampus and striatum of i.p. LPS-treated mice \[[@R35]\].

Flavonoids
----------

A group of dietary polyphenols, known as flavonoids, has been shown to inhibit inflammatory processes and to prevent age-related neurodegeneration and cognitive decline (reviewed in Refs \[[@R107],[@R108],[@R134],[@R135]\]). Their potential to attenuate neuroinflammation may be explained by inhibition of microglial activation and pro-inflammatory cytokines, as well as iNOS and COX-2 expression \[[@R107],[@R108]\].

Acacetin, the active compound of the crude extract of the leaves of Robinia pseudoacacia, has been shown to suppress microglia activation in i.p.LPS-treated adult male C57BL/6J mice after oral administration for 3 days \[[@R136]\].

It has been demonstrated that orally administered epigallocatechin-3-gallate (EGCG), the most abundant biologically active compound in tea, prevented memory impairment in 5-week-old male IcrTacSam:ICR mice caused by 7daily i.p. LPS injections, as determined by water maze and passive avoidance performance tests \[[@R137]\]. Moreover, authors observed inhibition of LPS-induced iNOS, COX-2 and GFAP expression in the brains of EGCG-administered mice, as determined by immunohistochemical analysis and Western blotting \[[@R138]\].

Purple sweet potato color (PSPC), a natural anthocyanin from the flavonoid family, has been shown to suppress iNOS, COX-2, TNF-α, IL-1β and IL-6 expression in LPS-treated mouse brain and to reverse the impairment of motor and exploration behavior induced by LPS \[[@R138]\].

CONCLUSIONS
===========

Neuroinflammation is now known to contribute to and exacerbate the pathology of neurodegenerative diseases. Better understanding of the mechanisms of neuro-inflammation induced by peripheral infection may lead to discovery of new therapeutic targets as well as new treatment approaches. The strategy of reducing inflammation in neurodegenerative disease has attracted increasing attention in recent years, and numerous synthetic and natural compounds are being tested in pre-clinical models as well as in clinical trials. However, more studies are needed to define which immune pathways or molecules, participating in inflammatory events leading to neurodegeneration, should be targeted. Importantly, we should always keep in mind that phenomena observed in mice may not occur in the same way in humans because of differences between mouse and human immune system (for a review see Ref. \[[@R139]\]). A systemic comparison of gene expression patterns in three inflammatory conditions -- trauma/hemorrhage, burn and endotoxemia- showed poor correlation between mouse and human immune responses \[[@R140]\]. However, in the latter study LPS was administered to mice in very low concentrations and it is not possible to compare their results with observations summarized and discussed in this review. Also, authors studied gene expression using blood samples and did not address neuroinflammation \[[@R140]\]. Nevertheless, we completely agree that although peripheral LPS-induced mouse model of neuroinflammation is an important tool for deciphering pathological mechanisms involved in neurodegeneration as well as for testing potential therapeutic molecules, caution is warranted when translating results to human studies.

Importantly, combination of strategies targeting simultaneously different pathological pathways, "systems therapeutics", may be more appropriate for a range of multifactorial neurodegenerative diseases with a known neuroinflammatory component.
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###### 

Summary of single LPS administration protocols and results.

  -----------------------------------------------------------------------------------------------------------------------
  Mouse Strain and Treatment Protocol              Results and Methods Applied                               Refs.
  ------------------------------------------------ --------------------------------------------------------- ------------
  BALB/c, young adult\* or old\*; LPS-0127:B8;\    Elevated IL-1β and IL-6 mRNA (RT-PCR)\                    \[[@R50]\]
  i.p.0.33mg/kg. Sacrificed at 4h                  and protein (ELISA)                                       

  Same protocol; Sacrificed at 24 h                Elevated IL-1β mRNA and IL-6 protein                      \[[@R50]\]

  BALB/c, old; same protocol; Sacrificed at 24 h   Elevated IL-1β and IL-6 mRNA and IL-6 protein             \[[@R50]\]

  C57BL/6J, ME7-infected (prion-disease model);\   Elevated IL-1β, IL-6 and TNF-α mRNA (RT-PCR)\             \[[@R37]\]
  i.p. 0.5mg/kg. Sacrificed at 6 h                 and IL-1β protein (ICH)                                   

  C57BL/6J; LPS-0111:B4; i.p.5mg/kg.\              Elevated TNF-α mRNA and protein (ELISA)                   \[[@R22]\]
  Sacrificed at 1 h, 14 and 21 days, 10 months                                                               

  BALB/c, young adult and old; LPS-0127:B8;\       Elevated IL-1β, IL-6 and TNF-α mRNA (RT-PCR)              \[[@R51]\]
  i.p.0.33mg/kg. Sacrificed at 4 h                                                                           

  BALB/c, young adult and old; LPS-0127:B8;\       Elevated IL-1β mRNA (RT-PCR) and protein (FACS)           \[[@R52]\]
  i.p. 0.33mg/kg. Sacrificed at 4 h or 8 h                                                                   

  C57BL/6J, young adult; LPS-026:B6;\              No effect observed                                        \[[@R53]\]
  i.p.2mg/kg. sacrificed at 4 h or 24 h                                                                      

  C57BL/6J, young adult; LPS-Salmonella\           Elevated IL-1β protein (ELISA)                            \[[@R35]\]
  Typhimurium; i.p.1mg/kg. Sacrificed at 4 days                                                              

  ICR, young; LPS-Salmonella Typhimurium;\         Elevated IL-6 protein (WB)                                \[[@R54]\]
  i.p.5mg/kg. Sacrificed at 24 h                                                                             

  C57BL/6J, young; LPS-0111:B4; i.p. 2mg/kg.\      Elevated IL-1β, IL-6 and TNF-α mRNA and protein           \[[@R55]\]
  Sacrificed at 24 h                                                                                         

  B6C3F1, young adult; LPS-0111:B4;\               No statistically significant production of IL-1β, IL-6\   \[[@R56]\]
  i.p. 10mg/kg. Sacrificed at 3 h                  and TNF-α protein (ELISA)                                 

  Same protocol. Sacrificed at 4,6 and 12 h        Elevated IL-6 protein (ELISA)                             \[[@R56]\]
  -----------------------------------------------------------------------------------------------------------------------

\*young mice: 2 months of age; young adult mice: 3-4 months of age; adult mice: 12-13 months of age; old or aged mice: 20 or more months old.

###### 

Summary of multiple LPS administration protocols and results.

  ------------------------------------------------------------------------------------------------------------------------
  Mouse Strain and Treatment                                 Results and Methods Applied                      Refs.
  --------------------------------------------------------- ------------------------------------------------- ------------
  3xTg-AD, young adult\*; LPS-055:B5; i.p. 0.5mg/kg;\       Elevated IL-1β but not IL-6 or TNF-α\             \[[@R27]\]
  twice per week/6 weeks. Sacrificed at 24h                 mRNA (RT-PCR)                                     

  3xTg-AD, adult\*; same protocol. Sacrificed at 48 h\      Elevated IL-6 protein (ELISA)- statistically\     \[[@R33]\]
                                                            significant\                                      
                                                            Elevated IL-1β protein (ELISA)- no statistical\   
                                                            significance achieved                             

  C57BL/6J, young adult; LPS-026:B6; i.p. 2mg/kg;\          Elevated IL-1β, IL-6 and TNF-α mRNA               \[[@R53]\]
  dual injection at 0 and 16 h. Sacrificed at 4 h or 24 h                                                     

  C57BL/6J; LPS-N/A; i.p. 0.25mg/kg; daily for 7 days.\     Elevated TNF-α and IL-1β mRNA                     \[[@R34]\]
  Sacrificed at 24 h                                                                                          

  B6C3F1, young adult; LPS-0111:B4; i.p. 10mg/kg;\          Elevated IL-1β, IL-6 and TNF-αprotein             \[[@R56]\]
  2 or 3 injections during 24 h. Sacrificed at 24 h                                                           

  B6C3F1, young adult; LPS-0111:B4; i.p. 0.5mg/kg;\         Elevated IL-1β and decreased TNF-α protein\       \[[@R56]\]
  every 3 days during 3 months.                             No changes in IL-6 protein (ELISA)                
  ------------------------------------------------------------------------------------------------------------------------

\*young mice: 2 months of age; young adult mice: 3-4 months of age; adult mice: 12-13 months of age; old or aged mice: 20 or more months old.
